aluates Reports

$ 0.0

Automative

Global Short-acting GLP-1 Therapy Market Research Report 2025

Published Date: November 2025

Report Code: QYRE-Auto-12T20153

BUY CHAPTERS

Global Short-acting GLP-1 Therapy Market Research Report 2025

Code: QYRE-Auto-12T20153

Report

November 2025

Pages:77

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Sanofi

Astrazeneca plc

Amneal Pharmaceuticals

Short-acting GLP-1 Therapy Market Size

The global market for Short-acting GLP-1 Therapy was valued at US$ 33652 million in the year 2024 and is projected to reach a revised size of US$ 102106 million by 2031, growing at a CAGR of 19.0% during the forecast period.

Short-acting GLP-1 Therapy Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Short-acting GLP-1 Therapy competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

Short-acting GLP-1 therapy refers to glucagon-like peptide-1 receptor agonists with brief systemic exposure (hours, not days), taken once- or twice-daily. They blunt post-meal glucose spikes mainly by slowing gastric emptying and enhancing glucose-dependent insulin release; effects on fasting glucose and weight are typically smaller than with weekly, long-acting agents. In 2024, global Short-acting GLP-1 Therapy production reached approximately 92961 K Unit, with an average global market price of around US$ 362 per unit.

Market outlook. Short-acting GLP-1 therapies (e.g., twice-daily or once-daily injectable analogs with strong post-prandial glucose effects via gastric-emptying delay) will remain a smaller, more price-sensitive niche versus long-acting weekly incretins, yet they retain strategic roles where prandial control is paramount—add-on to basal insulin, earlier T2D lines in cost-constrained markets, peri-prandial use in inpatient/acute settings, and for patients who poorly tolerate long-acting agents. Over the next 3–5 years, volume growth is expected to be modest in developed markets (offset by switching to weekly or dual agonists) but steadier in emerging regions and payer segments prioritizing lower acquisition cost, with upside from fixed-ratio basal insulin + short-acting GLP-1 combinations targeted at post-meal excursions.

Industry chain structure. Upstream includes peptide starting materials (protected amino acids, coupling reagents), solid-phase peptide synthesis capacity, purification (prep HPLC), and device components (disposable pens, safety needles), plus stabilizing excipients. Midstream originators and specialty generics/biosimilars firms formulate immediate-release injections, perform fill-finish into pens/cartridges, and run CMC, device human factors, and stability programs; CMOs/CDMOs increasingly supply peptide API and aseptic filling as capacity scales out of originators. Downstream, endocrinology and primary-care channels, diabetes clinics, and hospital formularies drive demand; payers influence persistence via tiering and step therapy, while retail/mail-order pharmacies and specialty distributors handle fulfillment and device training, with digital diabetes platforms adding adherence nudges and titration guidance.

Drivers and constraints. Demand is underpinned by prandial glucose control, rapid titration and reversibility (useful where GI tolerability is a concern), lower ASPs than weekly agents, and broad familiarity of daily pens. Headwinds are substantial: superior weight-loss and cardiometabolic data from once-weekly GLP-1s and next-gen incretin combos; patient preference for less frequent dosing; and growing obesity indications that favor long-acting molecules. Competitive strategies for short-acting players therefore center on value pricing, fixed-ratio co-formulations with basal insulin, hospital and peri-operative protocols, and regional tenders; lifecycle management focuses on pen usability, cold-chain robustness, and real-world evidence in PPG-dominant phenotypes (high CGM time-above-range post meals).

Economics and margin profile. Short-acting GLP-1s typically carry lower list prices and higher rebate pressure than weekly peers, but manufacturing costs (shorter peptide chains, simpler devices) are also lower.

Prospects. Expect a bifurcated market: in high-income regions, short-acting GLP-1s stabilize as adjuncts for PPG control (often in fixed-ratio or protocolized inpatient use); in cost-sensitive markets, they remain first-line incretin options where weekly analogs are unaffordable or supply-constrained. Manufacturers that pair competitive pricing with reliable supply, user-friendly pens, and evidence in CGM-defined PPG phenotypes can sustain share and healthy—if not peak—margins despite the class’s shift toward long-acting therapies.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Short-acting GLP-1 Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Short-acting GLP-1 Therapy.

The Short-acting GLP-1 Therapy market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Short-acting GLP-1 Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, by Feature and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Short-acting GLP-1 Therapy manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, by Feature and by regions.

Scope of Short-acting GLP-1 Therapy Market Report

Report Metric	Details
Report Name	Short-acting GLP-1 Therapy Market
Accounted market size in year	US$ 33652 million
Forecasted market size in 2031	US$ 102106 million
CAGR	19.0%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Injection Oral
Segment by Feature	GLP-1 Receptor Agonists Co-agonists
Segment by Channel	Online Sales Offline Sales
Segment by Application	Type 2 Diabetes Obesity/Weight Management Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Sanofi, AstraZeneca, Amneal Pharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Short-acting GLP-1 Therapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Short-acting GLP-1 Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Short-acting GLP-1 Therapy Market growing?

Ans: The Short-acting GLP-1 Therapy Market witnessing a CAGR of 19.0% during the forecast period 2025-2031.

What is the Short-acting GLP-1 Therapy Market size in 2031?

Ans: The Short-acting GLP-1 Therapy Market size in 2031 will be US$ 102106 million.

Who are the main players in the Short-acting GLP-1 Therapy Market report?

Ans: The main players in the Short-acting GLP-1 Therapy Market are Sanofi, AstraZeneca, Amneal Pharmaceuticals

What are the Application segmentation covered in the Short-acting GLP-1 Therapy Market report?

Ans: The Applications covered in the Short-acting GLP-1 Therapy Market report are Type 2 Diabetes, Obesity/Weight Management, Other

What are the Type segmentation covered in the Short-acting GLP-1 Therapy Market report?

Ans: The Types covered in the Short-acting GLP-1 Therapy Market report are Injection, Oral

1 Short-acting GLP-1 Therapy Market Overview

1.1 Product Definition

1.2 Short-acting GLP-1 Therapy by Type

1.2.1 Global Short-acting GLP-1 Therapy Market Value Comparison by Type (2024 VS 2031)

1.2.2 Injection

1.2.3 Oral

1.3 Short-acting GLP-1 Therapy by Feature

1.3.1 Global Short-acting GLP-1 Therapy Market Value Comparison by Feature: 2024 VS 2031

1.3.2 GLP-1 Receptor Agonists

1.3.3 Co-agonists

1.4 Short-acting GLP-1 Therapy by Channel

1.4.1 Global Short-acting GLP-1 Therapy Market Value Comparison by Channel: 2024 VS 2031

1.4.2 Online Sales

1.4.3 Offline Sales

1.5 Short-acting GLP-1 Therapy by Application

1.5.1 Global Short-acting GLP-1 Therapy Market Value by Application (2024 VS 2031)

1.5.2 Type 2 Diabetes

1.5.3 Obesity/Weight Management

1.5.4 Other

1.6 Global Short-acting GLP-1 Therapy Market Size Estimates and Forecasts

1.6.1 Global Short-acting GLP-1 Therapy Revenue 2020-2031

1.6.2 Global Short-acting GLP-1 Therapy Sales 2020-2031

1.6.3 Global Short-acting GLP-1 Therapy Market Average Price (2020-2031)

1.7 Assumptions and Limitations

2 Short-acting GLP-1 Therapy Market Competition by Manufacturers

2.1 Global Short-acting GLP-1 Therapy Sales Market Share by Manufacturers (2020-2025)

2.2 Global Short-acting GLP-1 Therapy Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Short-acting GLP-1 Therapy Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Short-acting GLP-1 Therapy, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Short-acting GLP-1 Therapy, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Short-acting GLP-1 Therapy, Product Type & Application

2.7 Global Key Manufacturers of Short-acting GLP-1 Therapy, Date of Enter into This Industry

2.8 Global Short-acting GLP-1 Therapy Market Competitive Situation and Trends

2.8.1 Global Short-acting GLP-1 Therapy Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Short-acting GLP-1 Therapy Players Market Share by Revenue

2.8.3 Global Short-acting GLP-1 Therapy Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Short-acting GLP-1 Therapy Market Scenario by Region

3.1 Global Short-acting GLP-1 Therapy Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Short-acting GLP-1 Therapy Sales by Region: 2020-2031

3.2.1 Global Short-acting GLP-1 Therapy Sales by Region: 2020-2025

3.2.2 Global Short-acting GLP-1 Therapy Sales by Region: 2026-2031

3.3 Global Short-acting GLP-1 Therapy Revenue by Region: 2020-2031

3.3.1 Global Short-acting GLP-1 Therapy Revenue by Region: 2020-2025

3.3.2 Global Short-acting GLP-1 Therapy Revenue by Region: 2026-2031

3.4 North America Short-acting GLP-1 Therapy Market Facts & Figures by Country

3.4.1 North America Short-acting GLP-1 Therapy Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Short-acting GLP-1 Therapy Sales by Country (2020-2031)

3.4.3 North America Short-acting GLP-1 Therapy Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe Short-acting GLP-1 Therapy Market Facts & Figures by Country

3.5.1 Europe Short-acting GLP-1 Therapy Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Short-acting GLP-1 Therapy Sales by Country (2020-2031)

3.5.3 Europe Short-acting GLP-1 Therapy Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Short-acting GLP-1 Therapy Market Facts & Figures by Region

3.6.1 Asia Pacific Short-acting GLP-1 Therapy Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Short-acting GLP-1 Therapy Sales by Region (2020-2031)

3.6.3 Asia Pacific Short-acting GLP-1 Therapy Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Short-acting GLP-1 Therapy Market Facts & Figures by Country

3.7.1 Latin America Short-acting GLP-1 Therapy Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Short-acting GLP-1 Therapy Sales by Country (2020-2031)

3.7.3 Latin America Short-acting GLP-1 Therapy Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Short-acting GLP-1 Therapy Market Facts & Figures by Country

3.8.1 Middle East and Africa Short-acting GLP-1 Therapy Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Short-acting GLP-1 Therapy Sales by Country (2020-2031)

3.8.3 Middle East and Africa Short-acting GLP-1 Therapy Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Short-acting GLP-1 Therapy Sales by Type (2020-2031)

4.1.1 Global Short-acting GLP-1 Therapy Sales by Type (2020-2025)

4.1.2 Global Short-acting GLP-1 Therapy Sales by Type (2026-2031)

4.1.3 Global Short-acting GLP-1 Therapy Sales Market Share by Type (2020-2031)

4.2 Global Short-acting GLP-1 Therapy Revenue by Type (2020-2031)

4.2.1 Global Short-acting GLP-1 Therapy Revenue by Type (2020-2025)

4.2.2 Global Short-acting GLP-1 Therapy Revenue by Type (2026-2031)

4.2.3 Global Short-acting GLP-1 Therapy Revenue Market Share by Type (2020-2031)

4.3 Global Short-acting GLP-1 Therapy Price by Type (2020-2031)

5 Segment by Application

5.1 Global Short-acting GLP-1 Therapy Sales by Application (2020-2031)

5.1.1 Global Short-acting GLP-1 Therapy Sales by Application (2020-2025)

5.1.2 Global Short-acting GLP-1 Therapy Sales by Application (2026-2031)

5.1.3 Global Short-acting GLP-1 Therapy Sales Market Share by Application (2020-2031)

5.2 Global Short-acting GLP-1 Therapy Revenue by Application (2020-2031)

5.2.1 Global Short-acting GLP-1 Therapy Revenue by Application (2020-2025)

5.2.2 Global Short-acting GLP-1 Therapy Revenue by Application (2026-2031)

5.2.3 Global Short-acting GLP-1 Therapy Revenue Market Share by Application (2020-2031)

5.3 Global Short-acting GLP-1 Therapy Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Sanofi

6.1.1 Sanofi Company Information

6.1.2 Sanofi Description and Business Overview

6.1.3 Sanofi Short-acting GLP-1 Therapy Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Sanofi Short-acting GLP-1 Therapy Product Portfolio

6.1.5 Sanofi Recent Developments/Updates

6.2 AstraZeneca

6.2.1 AstraZeneca Company Information

6.2.2 AstraZeneca Description and Business Overview

6.2.3 AstraZeneca Short-acting GLP-1 Therapy Sales, Revenue and Gross Margin (2020-2025)

6.2.4 AstraZeneca Short-acting GLP-1 Therapy Product Portfolio

6.2.5 AstraZeneca Recent Developments/Updates

6.3 Amneal Pharmaceuticals

6.3.1 Amneal Pharmaceuticals Company Information

6.3.2 Amneal Pharmaceuticals Description and Business Overview

6.3.3 Amneal Pharmaceuticals Short-acting GLP-1 Therapy Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Amneal Pharmaceuticals Short-acting GLP-1 Therapy Product Portfolio

6.3.5 Amneal Pharmaceuticals Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Short-acting GLP-1 Therapy Industry Chain Analysis

7.2 Short-acting GLP-1 Therapy Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Short-acting GLP-1 Therapy Production Mode & Process Analysis

7.4 Short-acting GLP-1 Therapy Sales and Marketing

7.4.1 Short-acting GLP-1 Therapy Sales Channels

7.4.2 Short-acting GLP-1 Therapy Distributors

7.5 Short-acting GLP-1 Therapy Customer Analysis

8 Short-acting GLP-1 Therapy Market Dynamics

8.1 Short-acting GLP-1 Therapy Industry Trends

8.2 Short-acting GLP-1 Therapy Market Drivers

8.3 Short-acting GLP-1 Therapy Market Challenges

8.4 Short-acting GLP-1 Therapy Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Sanofi

Astrazeneca plc

Amneal Pharmaceuticals

List of Tables

Table 1. Global Short-acting GLP-1 Therapy Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Short-acting GLP-1 Therapy Market Value by Feature, (US$ Million) & (2024 VS 2031)

Table 3. Global Short-acting GLP-1 Therapy Market Value by Channel, (US$ Million) & (2024 VS 2031)

Table 4. Global Short-acting GLP-1 Therapy Market Value by Application (2024 VS 2031) & (US$ Million)

Table 5. Global Short-acting GLP-1 Therapy Market Competitive Situation by Manufacturers in 2024

Table 6. Global Short-acting GLP-1 Therapy Sales (K Units) of Key Manufacturers (2020-2025)

Table 7. Global Short-acting GLP-1 Therapy Sales Market Share by Manufacturers (2020-2025)

Table 8. Global Short-acting GLP-1 Therapy Revenue (US$ Million) by Manufacturers (2020-2025)

Table 9. Global Short-acting GLP-1 Therapy Revenue Share by Manufacturers (2020-2025)

Table 10. Global Market Short-acting GLP-1 Therapy Average Price (US$/Unit) of Key Manufacturers (2020-2025)

Table 11. Global Key Players of Short-acting GLP-1 Therapy, Industry Ranking, 2022 VS 2023 VS 2024

Table 12. Global Key Manufacturers of Short-acting GLP-1 Therapy, Manufacturing Sites & Headquarters

Table 13. Global Key Manufacturers of Short-acting GLP-1 Therapy, Product Type & Application

Table 14. Global Key Manufacturers of Short-acting GLP-1 Therapy, Date of Enter into This Industry

Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 16. Global Short-acting GLP-1 Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Short-acting GLP-1 Therapy as of 2024)

Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 18. Global Short-acting GLP-1 Therapy Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 19. Global Short-acting GLP-1 Therapy Sales by Region (2020-2025) & (K Units)

Table 20. Global Short-acting GLP-1 Therapy Sales Market Share by Region (2020-2025)

Table 21. Global Short-acting GLP-1 Therapy Sales by Region (2026-2031) & (K Units)

Table 22. Global Short-acting GLP-1 Therapy Sales Market Share by Region (2026-2031)

Table 23. Global Short-acting GLP-1 Therapy Revenue by Region (2020-2025) & (US$ Million)

Table 24. Global Short-acting GLP-1 Therapy Revenue Market Share by Region (2020-2025)

Table 25. Global Short-acting GLP-1 Therapy Revenue by Region (2026-2031) & (US$ Million)

Table 26. Global Short-acting GLP-1 Therapy Revenue Market Share by Region (2026-2031)

Table 27. North America Short-acting GLP-1 Therapy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 28. North America Short-acting GLP-1 Therapy Sales by Country (2020-2025) & (K Units)

Table 29. North America Short-acting GLP-1 Therapy Sales by Country (2026-2031) & (K Units)

Table 30. North America Short-acting GLP-1 Therapy Revenue by Country (2020-2025) & (US$ Million)

Table 31. North America Short-acting GLP-1 Therapy Revenue by Country (2026-2031) & (US$ Million)

Table 32. Europe Short-acting GLP-1 Therapy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 33. Europe Short-acting GLP-1 Therapy Sales by Country (2020-2025) & (K Units)

Table 34. Europe Short-acting GLP-1 Therapy Sales by Country (2026-2031) & (K Units)

Table 35. Europe Short-acting GLP-1 Therapy Revenue by Country (2020-2025) & (US$ Million)

Table 36. Europe Short-acting GLP-1 Therapy Revenue by Country (2026-2031) & (US$ Million)

Table 37. Asia Pacific Short-acting GLP-1 Therapy Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 38. Asia Pacific Short-acting GLP-1 Therapy Sales by Region (2020-2025) & (K Units)

Table 39. Asia Pacific Short-acting GLP-1 Therapy Sales by Region (2026-2031) & (K Units)

Table 40. Asia Pacific Short-acting GLP-1 Therapy Revenue by Region (2020-2025) & (US$ Million)

Table 41. Asia Pacific Short-acting GLP-1 Therapy Revenue by Region (2026-2031) & (US$ Million)

Table 42. Latin America Short-acting GLP-1 Therapy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 43. Latin America Short-acting GLP-1 Therapy Sales by Country (2020-2025) & (K Units)

Table 44. Latin America Short-acting GLP-1 Therapy Sales by Country (2026-2031) & (K Units)

Table 45. Latin America Short-acting GLP-1 Therapy Revenue by Country (2020-2025) & (US$ Million)

Table 46. Latin America Short-acting GLP-1 Therapy Revenue by Country (2026-2031) & (US$ Million)

Table 47. Middle East and Africa Short-acting GLP-1 Therapy Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 48. Middle East and Africa Short-acting GLP-1 Therapy Sales by Country (2020-2025) & (K Units)

Table 49. Middle East and Africa Short-acting GLP-1 Therapy Sales by Country (2026-2031) & (K Units)

Table 50. Middle East and Africa Short-acting GLP-1 Therapy Revenue by Country (2020-2025) & (US$ Million)

Table 51. Middle East and Africa Short-acting GLP-1 Therapy Revenue by Country (2026-2031) & (US$ Million)

Table 52. Global Short-acting GLP-1 Therapy Sales (K Units) by Type (2020-2025)

Table 53. Global Short-acting GLP-1 Therapy Sales (K Units) by Type (2026-2031)

Table 54. Global Short-acting GLP-1 Therapy Sales Market Share by Type (2020-2025)

Table 55. Global Short-acting GLP-1 Therapy Sales Market Share by Type (2026-2031)

Table 56. Global Short-acting GLP-1 Therapy Revenue (US$ Million) by Type (2020-2025)

Table 57. Global Short-acting GLP-1 Therapy Revenue (US$ Million) by Type (2026-2031)

Table 58. Global Short-acting GLP-1 Therapy Revenue Market Share by Type (2020-2025)

Table 59. Global Short-acting GLP-1 Therapy Revenue Market Share by Type (2026-2031)

Table 60. Global Short-acting GLP-1 Therapy Price (US$/Unit) by Type (2020-2025)

Table 61. Global Short-acting GLP-1 Therapy Price (US$/Unit) by Type (2026-2031)

Table 62. Global Short-acting GLP-1 Therapy Sales (K Units) by Application (2020-2025)

Table 63. Global Short-acting GLP-1 Therapy Sales (K Units) by Application (2026-2031)

Table 64. Global Short-acting GLP-1 Therapy Sales Market Share by Application (2020-2025)

Table 65. Global Short-acting GLP-1 Therapy Sales Market Share by Application (2026-2031)

Table 66. Global Short-acting GLP-1 Therapy Revenue (US$ Million) by Application (2020-2025)

Table 67. Global Short-acting GLP-1 Therapy Revenue (US$ Million) by Application (2026-2031)

Table 68. Global Short-acting GLP-1 Therapy Revenue Market Share by Application (2020-2025)

Table 69. Global Short-acting GLP-1 Therapy Revenue Market Share by Application (2026-2031)

Table 70. Global Short-acting GLP-1 Therapy Price (US$/Unit) by Application (2020-2025)

Table 71. Global Short-acting GLP-1 Therapy Price (US$/Unit) by Application (2026-2031)

Table 72. Sanofi Company Information

Table 73. Sanofi Description and Business Overview

Table 74. Sanofi Short-acting GLP-1 Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 75. Sanofi Short-acting GLP-1 Therapy Product

Table 76. Sanofi Recent Developments/Updates

Table 77. AstraZeneca Company Information

Table 78. AstraZeneca Description and Business Overview

Table 79. AstraZeneca Short-acting GLP-1 Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 80. AstraZeneca Short-acting GLP-1 Therapy Product

Table 81. AstraZeneca Recent Developments/Updates

Table 82. Amneal Pharmaceuticals Company Information

Table 83. Amneal Pharmaceuticals Description and Business Overview

Table 84. Amneal Pharmaceuticals Short-acting GLP-1 Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 85. Amneal Pharmaceuticals Short-acting GLP-1 Therapy Product

Table 86. Amneal Pharmaceuticals Recent Developments/Updates

Table 87. Key Raw Materials Lists

Table 88. Raw Materials Key Suppliers Lists

Table 89. Short-acting GLP-1 Therapy Distributors List

Table 90. Short-acting GLP-1 Therapy Customers List

Table 91. Short-acting GLP-1 Therapy Market Trends

Table 92. Short-acting GLP-1 Therapy Market Drivers

Table 93. Short-acting GLP-1 Therapy Market Challenges

Table 94. Short-acting GLP-1 Therapy Market Restraints

Table 95. Research Programs/Design for This Report

Table 96. Key Data Information from Secondary Sources

Table 97. Key Data Information from Primary Sources

Table 98. Authors List of This Report

List of Figures

Figure 1. Product Picture of Short-acting GLP-1 Therapy

Figure 2. Global Short-acting GLP-1 Therapy Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Short-acting GLP-1 Therapy Market Share by Type: 2024 & 2031

Figure 4. Injection Product Picture

Figure 5. Oral Product Picture

Figure 6. Global Short-acting GLP-1 Therapy Market Value by Feature, (US$ Million) & (2020-2031)

Figure 7. Global Short-acting GLP-1 Therapy Market Share by Feature: 2024 VS 2031

Figure 8. GLP-1 Receptor Agonists Product Picture

Figure 9. Co-agonists Product Picture

Figure 10. Global Short-acting GLP-1 Therapy Market Value by Channel, (US$ Million) & (2020-2031)

Figure 11. Global Short-acting GLP-1 Therapy Market Share by Channel: 2024 VS 2031

Figure 12. Online Sales Product Picture

Figure 13. Offline Sales Product Picture

Figure 14. Global Short-acting GLP-1 Therapy Market Value by Application (2020-2031) & (US$ Million)

Figure 15. Global Short-acting GLP-1 Therapy Market Share by Application: 2024 & 2031

Figure 16. Type 2 Diabetes

Figure 17. Obesity/Weight Management

Figure 18. Other

Figure 19. Global Short-acting GLP-1 Therapy Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 20. Global Short-acting GLP-1 Therapy Market Size (2020-2031) & (US$ Million)

Figure 21. Global Short-acting GLP-1 Therapy Sales (2020-2031) & (K Units)

Figure 22. Global Short-acting GLP-1 Therapy Average Price (US$/Unit) & (2020-2031)

Figure 23. Short-acting GLP-1 Therapy Report Years Considered

Figure 24. Short-acting GLP-1 Therapy Sales Share by Manufacturers in 2024

Figure 25. Global Short-acting GLP-1 Therapy Revenue Share by Manufacturers in 2024

Figure 26. Global 5 and 10 Largest Short-acting GLP-1 Therapy Players: Market Share by Revenue in Short-acting GLP-1 Therapy in 2024

Figure 27. Short-acting GLP-1 Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 28. Global Short-acting GLP-1 Therapy Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 29. North America Short-acting GLP-1 Therapy Sales Market Share by Country (2020-2031)

Figure 30. North America Short-acting GLP-1 Therapy Revenue Market Share by Country (2020-2031)

Figure 31. United States Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Canada Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Europe Short-acting GLP-1 Therapy Sales Market Share by Country (2020-2031)

Figure 34. Europe Short-acting GLP-1 Therapy Revenue Market Share by Country (2020-2031)

Figure 35. Germany Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. France Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. U.K. Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. Italy Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Russia Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Asia Pacific Short-acting GLP-1 Therapy Sales Market Share by Region (2020-2031)

Figure 41. Asia Pacific Short-acting GLP-1 Therapy Revenue Market Share by Region (2020-2031)

Figure 42. China Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Japan Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. South Korea Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. India Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Australia Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. China Taiwan Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Southeast Asia Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Latin America Short-acting GLP-1 Therapy Sales Market Share by Country (2020-2031)

Figure 50. Latin America Short-acting GLP-1 Therapy Revenue Market Share by Country (2020-2031)

Figure 51. Mexico Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Brazil Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. Argentina Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. Colombia Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 55. Middle East and Africa Short-acting GLP-1 Therapy Sales Market Share by Country (2020-2031)

Figure 56. Middle East and Africa Short-acting GLP-1 Therapy Revenue Market Share by Country (2020-2031)

Figure 57. Turkey Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 58. Saudi Arabia Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 59. UAE Short-acting GLP-1 Therapy Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 60. Global Sales Market Share of Short-acting GLP-1 Therapy by Type (2020-2031)

Figure 61. Global Revenue Market Share of Short-acting GLP-1 Therapy by Type (2020-2031)

Figure 62. Global Short-acting GLP-1 Therapy Price (US$/Unit) by Type (2020-2031)

Figure 63. Global Sales Market Share of Short-acting GLP-1 Therapy by Application (2020-2031)

Figure 64. Global Revenue Market Share of Short-acting GLP-1 Therapy by Application (2020-2031)

Figure 65. Global Short-acting GLP-1 Therapy Price (US$/Unit) by Application (2020-2031)

Figure 66. Short-acting GLP-1 Therapy Value Chain

Figure 67. Channels of Distribution (Direct Vs Distribution)

Figure 68. Bottom-up and Top-down Approaches for This Report

Figure 69. Data Triangulation

Figure 70. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions